Rallybio (NASDAQ:RLYB – Get Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter.
Rallybio Stock Performance
RLYB stock opened at $0.74 on Monday. Rallybio has a fifty-two week low of $0.68 and a fifty-two week high of $3.46. The business’s 50 day moving average price is $0.84 and its two-hundred day moving average price is $0.99. The company has a market capitalization of $30.87 million, a price-to-earnings ratio of -0.46 and a beta of -1.45.
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Rallybio in a research report on Wednesday, February 12th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $9.75.
Rallybio Company Profile
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.
Featured Stories
- Five stocks we like better than Rallybio
- Stock Market Upgrades: What Are They?
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- Most Volatile Stocks, What Investors Need to Know
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- What Are Dividend Champions? How to Invest in the Champions
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.